HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $115
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $100 to $115.
HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $100 to $115.
